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Abstract: Following infection, lymphocytes expand
exponentially and differentiate into effector cells to
control infection and coordinate the multiple effector
arms of the immune response. Soon after this expansion,
the majority of antigen-specific lymphocytes die, thus
keeping homeostasis, and a small pool of memory cells
develops, providing long-term immunity to subsequent
reinfection. The extent of infection and rate of pathogen
clearance are thought to determine both the magnitude
of cell expansion and the homeostatic contraction to a
stable number of memory cells. This straight correlation
between the kinetics of T cell response and the dynamics
of lymphoid tissue cell numbers is a constant feature in
acute infections yielded by pathogens that are cleared
during the course of response. However, the regional
dynamics of the immune response mounted against
pathogens that are able to establish a persistent infection
remain poorly understood. Herein we discuss the
differential lymphocyte dynamics in distinct central and
peripheral lymphoid organs following acute infection by
Trypanosoma cruzi, the causative agent of Chagas disease.
While the thymus and mesenteric lymph nodes undergo a
severe atrophy with massive lymphocyte depletion, the
spleen and subcutaneous lymph nodes expand due to T
and B cell activation/proliferation. These events are
regulated by cytokines, as well as parasite-derived
moieties. In this regard, identifying the molecular
mechanisms underlying regional lymphocyte dynamics
secondary to T. cruzi infection may hopefully contribute to
the design of novel immune intervention strategies to
control pathology in this infection.
Introduction
Chagas disease is caused by the protozoan Trypanosoma cruzi.
The infection was initially rural in endemic areas in Latin
America, transmitted by contaminated insect vectors of the family
Reduviidae. Insects become vectors after biting T. cruzi-infected
hosts (animals or humans). Parasites may also be transmitted by
blood transfusion, by organ transplantation, orally, and congen-
itally. For this reason, Chagas disease is emerging in non-endemic
countries such as Japan, Canada, Germany, Romania, Spain, and
the United States [1,2]. It is estimated that 14–16 million people in
Latin America and 1 million in the US are infected with T. cruzi
with 670,000 premature disabilities and deaths per year worldwide
[1–3]. The infection is considered a world health problem and a
neglected tropical disease with deficiencies in treatment, absence
of appropriated vaccines, and world spreading [4,5]. The
complexity in treatment is related to the fact that current
chemotherapic drugs Benznidazole and Nifurtimox are able to
heal only a portion of recent infections, have severe side effects,
and are active only in the acute phase and short-term chronic
phase of infection [2].
Considered a ‘‘silent killer,’’ infection with T. cruzi leads to an
acute phase, with symptoms such as fever, muscle pain, swollen
lymph nodes, hepatosplenomegaly, pericardial effusion, and
inflammatory reaction at the vector’s biting site (chagoma) [2,6].
During the acute phase, circulating parasites are numerous and
able to infect several tissues in the host, including skeletal muscle,
lymphoid tissues, nervous tissues, and glands [5,7]. In humans, the
acute phase is short (two months) and may lead to complications
such as myocarditis or meningoencephalitis. Spontaneous recovery
occurs in more than 95% of the patients [8]. Following the acute
phase, the patient enters into a long indeterminate latent phase
with no symptoms and very low parasitism. The latent infection
remains silent for 10 to 30 years. About one third of infected
patients in the latent phase develop clinical symptoms such as
chronic cardiac dysfunction (cardiomyopathy), megacolon, or
megaesophagus. The average life expectancy decreases about nine
years in these clinical forms of chronic chagasic patients [8].
Experimental models of T. cruzi infection have been widely used
to study various aspects of the infection, and the vast majority of
knowledge of the biology of T. cruzi infection was first developed in
the experimental mouse model. Acute infection in mice leads to
strong activation of innate and adaptive immune response.
Splenomegaly and expansion in subcutaneous lymph nodes
(SCLN) were reported, with persistent T and B cell polyclonal
activation (Figure 1) [9–11]. Conversely, atrophy in thymus and
mesenteric lymph nodes (MLN) was also observed in the infection
(Figure 1) [12–14].
Thus, it is conceivable that the immune response to T. cruzi
infection is complex, and differential patterns of responses may
occur in distinct compartments of the immune system, including
cell expansion, cytokine production, and cell death. In this context,
we review herein a number of findings showing that in the course
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Thymocyte Depletion and Differential Cytokine
Profile in T. cruzi Infection
The thymus is a primary lymphoid organ in which bone marrow-
derived T cell precursors undergo differentiation, leading to
migration of positively selected thymocytes to the T cell-dependent
areas of secondary lymphoid organs [15]. This tissue is a target
organ inT. cruziinfectioninmice, wheretheparasite is able to infect
thymic microenvironmental cells in vivo and in vitro [5,12,14]
(Figure 2). Ultrastructural analysis of infected thymus indicates that
phagocytic and epithelial cells can be infected in vivo [16].
Acute T. cruzi infection leads to thymus atrophy, with loss of
thymus weight, decline in cell number, and depletion of
CD4
+CD8
+ (DP) thymocytes [5,14,17–19]. Thymocyte depletion
is detectable in early stages of infection and increases along with
time until the peak of parasitemia (Figures 1 and 2). The loss of
thymocytes observed in the acute phase of infection is apparently
due to differences not only in cell death, but also in proliferation
and migration of thymocytes.
Mitogenic responses of thymocytes from acutely infected mice is
reduced due to decrease in interleukin (IL)-2 production, which in
turn is associated with high levels of IL-10 and interferon (IFN)-c
[20]. Additionally, increased production of IL-4, IL-5, and IL-6
was detected in thymocytes from acutely infected mice, being
related to thymocyte cytotoxic activities [20].
Abnormal thymocyte migration is also observed in the thymus
of infected mice. In vitro studies of thymocyte migration in thymic
nurse cells (TNCs, specialized cortical thymic epithelial cells that
harbor and release immature thymocytes as a consequence of cell
migration) following in vivo and in vitro infection demonstrated
that thymocytes from infected TNC complexes are released faster
than the corresponding controls [5,14,21]. These studies suggested
an increase in the migratory capacity of thymocytes from infected
mice. In fact, the increase in DP cell migration from thymus to
peripheral lymphoid organs seen in both acutely and chronically
infected mice corroborates this hypothesis [14,21,22]. Phenotypic
analysis of DP lymphocytes in SCLN from T. cruzi-infected
BALB/c mice demonstrated that part of these cells expresses
‘‘forbidden’’ T cell receptors and high amounts of cell migration-
related membrane receptors, including the integrins VLA-4, VLA-
5 (fibronectin receptors), and VLA-6 (laminin receptors) [5,21,22].
Figure 1. Differential fluctuations in the cellularity of the thymus, spleen, MLN, and SCLN in the course of acute T. cruzi infection.
Note a lymphocyte expansion in the spleen and SCLN, in parallel to a lymphocyte decrease in the thymus and MLN. BALB/c mice were infected
intraperitoneally with 10
2 blood trypomastigotes of the Tulahue ´n strain, killed at different days of infection, and cell numbers evaluated by trypan
blue exclusion. Erythrocytes were previously depleted in the spleen cell suspensions by treatment with Tris-buffered ammonium chloride. Values
represent the mean6standard error; n=3–5 mice/group in each point. Data recorded on thymus, spleen, MLN, and SCLN from T. cruzi-infected mice
(closed squares) were compared to non-infected age-matched controls (open squares) with ANOVA statistical test, using the program SigmaStat
(Statistical Software) for Windows. Data were considered significant if p values were ,0.05. Data represent mean6standard error. All experiments and
animal handling were conducted according to protocols approved by the Oswaldo Cruz Foundation Committee on the Use of Animals.
doi:10.1371/journal.pntd.0000417.g001
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mal thymocyte migration seen in infected mice. Several studies
demonstrated that in these animals the thymus exhibits enhanced
deposition of extracellular matrix proteins such as fibronectin,
laminin, and type IV collagen, increased chemokine contents such
as CXCL12, and expression of de-adhesive molecules such as
galectin-3. Ex vivo cell migration experiments revealed that all
these molecules would favor the abnormal release of DP
thymocytes to peripheral lymphoid organs [5,12,21,23,24].
Independent research groups reported molecules involved in
thymocyte death following experimental T. cruzi infection, com-
prising parasite- or host-derived factors. Examples of the participa-
tion of host-derived stimuli in thymocyte apoptosis are galectin-3,
extracellular ATP, and glucocorticoid hormones [23,25–27].
Interestingly, DP thymocyte depletion inside TNCs is dependent
on androgens, and the intracellular thymocyte pathway of celldeath
leads to activation of caspase-3 [28]. Conversely, Fas and perforin
are not involved in thymus atrophy in T. cruzi infection [19]. In
relation to T. cruzi-derived molecules, it has been reported that the
virulence factortrans-sialidase, an enzyme that alterscell sialylation,
promotes apoptosis of DP thymocytes [29,30].
Thymus alterations in T. cruzi infection occur concomitantly to
the increasing parasitemia, suggesting that thymus atrophy is
dependent on the parasite load [16,21]. Corroborating this
hypothesis, mice treated with benznidazole in the course of
infection show reduction in blood parasitemia and no thymus
alterations during infection [31]. Another interesting finding is that
chronically infected mice do not exhibit significant reduction of
thymus weight, cell number, and DP thymocytes, as compared with
age-matched normal mice (Figure 2A) [32]. The similarity between
normal and infected thymocyte cell number in the chronic phase
might be related to the fact that in normal mice, thymocyte
depletion is observed along with aging [33] (Figure 2A). The impact
of thymus alterations during acute infection with respect to the
development of effector immune response is still unknown. It is
reasonable to think that a decline in the generation of T cells
together with an abnormal release of non-selected thymocytes
during acute infection would favor the parasite rather than the host.
In fact, T lymphocytes are crucial for mounting an effective anti-T.
cruzi immune response: athymic nude mice infected with T. cruzi
show increased parasitemia and mortality rate and shortened
survival time [16,34]. On the other hand, it was previously
Figure 2. The thymus is a target organ in T. cruzi infection. Panel A shows the number of thymocytes in thymus of T. cruzi-infected mice (C3H/
HeJ) during acute (one month) and chronic phases (after three to five months) of infection. Adapted from [32], *p,0.01. Panel B reveals the presence
of the amastigote forms of the Colombian strain of T. cruzi within cultured thymic epithelial cells, ascertained by DAPI staining. Note that one cell
(arrow) is deeply loaded with trypomastigote forms of the parasite in the cytoplasm. The mouse TEC line (IT-76M1) was cultured with 60 T. cruzi
trypomastigotes/TEC for six hours; washed to remove free parasites, and cultured for a further 48 hours. Panel C shows a progressive thymocyte
depletion in mice acutely infected with T. cruzi. BALB/c mice were infected intraperitoneally with 10
2 blood-derived trypomastigotes of the Tulahue ´n
strain, and killed at 14 and 19 days post-infection (d.p.i.). Percentage values of the CD4
+CD8
+ thymocytes and respective days post-infection are
shown. In normal animals, the percentage of CD4
+CD8
+ thymocytes remained the same along with the experimental period.
doi:10.1371/journal.pntd.0000417.g002
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suppressor effects on the host immune response [35].
Taken together, these data support the idea that T. cruzi
infection promotes disturbances of proliferation, migration, and
cell death within the thymus.
T Cell Depletion in Peyer’s Patches and MLN
Following T. cruzi Infection
The mucosal immune system remains less studied than it should
be in T. cruzi infection. Such studies are necessary since: (1) the
prognosis of the chronic phase depends on the evolution of the
acute phase and the parasite is able to infect gut tissues; (2) chronic
patients with Chagas disease may progress with digestive forms of
clinical manifestations, namely megacolon and megaesophagus (in
Brazil, the incidence of megaesophagus in endemic areas is over
8%); and (3) oral transmission of the parasite in humans through
ingestion of fruit juice contaminated with T. cruzi recently
occurred in Brazil, leading to a severe and sometimes lethal acute
disease [36–39].
The Peyer’s patches (PP) are important lymphoid organs
implicated in mucosal immune response. PP are separated from
the intestinal lumen by a layer of epithelial cells known as the
follicle-associated epithelium, in which the so-called M cells are
involved in mucosal immune responses, binding invasive patho-
gens and passing them to professional antigen-presenting cells
inside PP. After encountering the antigen, antigen-presenting cells
(mainly dendritic cells) migrate to T cell areas where they interact
and activate T cells. Lymphocytes and dendritic cells that are
primed in PP migrate to MLN through draining lymphatic vessels.
Considering that PP and MLN drain antigens from the small
intestine and that chronic infection may progress with damage to
the digestive tract, MLN and PP might have some relation to gut
pathologies in infected patients. Very little information is available
regarding the immunological response of chronic chagasic patients
with gastrointestinal forms of the disease, and none of these works
analyze gut-associated lymphoid tissues or MLN. It is known that
patients with digestive forms of the disease present high
parasitemia and decreased T/B lymphocyte numbers in their
blood [40]. Moreover, peripheral blood mononuclear cells
(PBMCs) from esophagopathy patients produce high levels of
inflammatory cytokines such as IFN-c and MIG and low levels of
tumor necrosis factor (TNF)-a, with no significant differences in
IL-4 and IL-5 production [41].
In experimental animal models, T. cruzi infection induces
several forms of damage in gut-associated lymphoid tissues. PP
from infected mice show reduction in size, number, and cellularity,
due to an increase in T and B lymphocyte depletion [42]. MLN
also undergo severe atrophy in acute infection in several models of
T. cruzi infection [13,43] (Figure 1). The diminished number of
MLN lymphocytes in infected mice seems to be associated with
differences in lymphocyte proliferation and death. MLN from T.
cruzi-infected mice show reduced numbers of proliferating
lymphocytes and decreased cytokine production (IL-2, IL-4, and
IL-10) by activated T lymphocytes, as summarized in Table 1
[13,44]. Interestingly, MLN T lymphocytes produce mainly type-1
cytokines (IFN-c) upon infection with T. cruzi [44]. Increased
lymphocyte death is also observed in MLN from T. cruzi-infected
mice [13,44].
T cell apoptosis can be stimulated in secondary lymphoid
organs by activation-induced cell death (AICD) or growth factor
withdrawal [45]. The abundance of antigens and cytokine
production (IL-2 and IL-4) in the lymphoid microenvironment
are essential to trigger the cell death pathway [45]. In the presence
of an antigen, IL-2 prompts T cells to die by AICD, through
activation of death receptor molecules and caspase-8 [46–48]. In
the absence of antigen, deprivation of cytokines initiates the
mitochondrial death pathway, promoting cytochrome c release
into the cytoplasm and activating caspase-9 and downstream
effector caspases [46]. In MLN from mice acutely infected with T.
cruzi, T/B lymphocyte apoptosis occurs in early stages of infection
through AICD and growth factor withdrawal mechanisms [13,44].
Studies performed with the Colombian strain of T. cruzi in FasL
mutant mice (gld) and TNF receptor-1 knockout mice suggested
that these molecules are involved in MLN lymphocyte apoptosis
from infected mice [13]. Moreover, acute infection with the
Dm28c clone of the parasite led to IL-4 deprivation and caspase-9
activation, promoting MLN atrophy with T cell depletion [44].
Depletion of MLN lymphocytes impairs immune response
against the parasite, since MLN excision prior to infection
increases host susceptibility to infection [44]. Interestingly, in vivo
administration of zVAD-fmk (a pan-caspase inhibitor) in the
course of infection prevents MLN atrophy, reduces lymphocyte
apoptosis in secondary lymphoid tissues, and increases host
resistance to infection [44,49]. Moreover, oral vaccination with
Salmonella enterica carrying cruzipain showed protective immune
response against the parasite with reduction of tissue damage of
infected mice [50], thus showing that mucosa-associated lymphoid
cells are important to host immunity in T. cruzi infection, and that
the parasite is able to promote lymphocyte depletion and defective
cytokine response in these tissues.
Acute T. cruzi Infection Induces Expansion of T
Cells in SCLN
SCLN are strategically distributed throughout the body,
receiving antigens captured from the epidermis and several other
epithelia. The most studied SCLN in T. cruzi infection are the
Table 1. Differential cytokine and apoptosis/proliferation profiles in lymphoid organs of mice undergoing T. cruzi infection.
Response to Infection Thymus MLN SCLN Spleen References
Apoptosis qq qq q q [13,23,25,44,49,51,72,73,85]
Proliferation QQ Q q q q q [11,13,56,57,86]
IL-2 QQ q /= Q [44,65–67]
INF-c qq Q qq qq [20,44,49,51,65]
IL-4 qq QQ qq q [20,44,51,52,68]
IL-10 qq QQ qq qq [20,44,51,52,68]
Differences between normal versus infected mice are indicated with the arrows.
doi:10.1371/journal.pntd.0000417.t001
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infections promote a significant increase in SCLN size and cell
numbers in mice and humans. Studies performed in mice
demonstrated that infection leads to increase of cycling cells,
which are able to produce IL-2 and proliferate after in vitro
activation [44]. Several studies reported polyclonal activation of
T/B lymphocytes in SCLN from acutely and chronically infected
mice [9–11].
Effector T lymphocytes from SCLN of infected mice secrete
high levels of IL-4, IL-10, and IFN-c [44]. These data suggest that
T lymphocyte response in SCLN is quite distinct from MLN in
acute infection, with increased production of both type-1 and type-
2 cytokines, as summarized in Table 1 [44].
T and B lymphocyte apoptosis is also observed in SCLN from
infected mice, mainly in the latter stages of infection [13].
Apoptosis in SCLN seems to be induced by AICD, due to control
of an extensive state of cell activation. In agreement with this
notion, it has been shown that in vivo injection of anti-FasL
antibody or zVAD-fmk in acutely infected mice increased the
numbers of T/B lymphocytes in SCLN and improved the host
immune response to infection [49,51]. Trans-sialidase seems also
to be involved in lymphocyte apoptosis in SCLN from infected
mice [30].
Taken together, the data discussed above show that SCLN and
MLN lymphocytes are distinctly affected in T. cruzi acute infection,
with different patterns of T cell activation, proliferation, cytokine
responses, and cell death.
Splenomegaly Is a Constant Feature in T. cruzi
Infection
T. cruzi infection promotes splenomegaly in mice and humans.
In mice, splenomegaly is observed in both acute and chronic
phases of disease. Splenocytes are important cells involved in the
host immune response since splenectomy prior to infection
increases susceptibility to infection, as ascertained by the numbers
of circulating parasites (Figure 3).
Infection promotes spleen T/B lymphocyte activation and
expansion. In this respect, trans-sialidase seems to contribute to
polyclonal lymphocyte activation and cytokine production by
interfering with interaction between dendritic cells and T
lymphocytes [52–54]. Additionally, other parasite-derived mole-
cules such as racemase and DNA (via Toll-like receptor 9) were
proven to induce B cell proliferation [55–57].
Although parasite-driven proteins are able to induce B cell
expansion, the relative contribution of B cells in acquired
resistance upon T. cruzi infection remains open to discussion
[58]. B cell-deficient mice show increased mortality rates at late
stages of infection and a delayed rise in parasitemia, with deficient
ability to remove bloodstream trypomastigotes from the circulation
[59–62]. By contrast, polyclonal B cell activation contributes to the
pathological alterations seen in Chagas disease. Antibodies are
involved in wasting mice, and auto-reactive antibodies against
endocardium and nerves are detected in both mice and humans
[63,64].
Previous data in the literature demonstrated that IL-2 and T
lymphocyte proliferation of concanavalin A-stimulated splenocytes
from acutely infected mice is depressed [65,66]. This IL-2
suppression is usually observed in early stages of infection with
virulent parasite strains (proportional to stages of high parasite
loads) [66,67]. Activated T lymphocytes in the spleen from T.
cruzi-infected mice secrete IFN-c, IL-4, and IL-10, suggesting a
type-1 and type-2 mixed profile of cytokine secretion, similar to
what is found in SCLN [68]. In humans, co-culture of PBMCs
from normal patients with irradiated T. cruzi promotes T/B
lymphocyte proliferation and secretion of cytokines as IL-1b, IL-2,
IL-5, IL-6, IFN-c, and TNF-a [69].
AICD is observed in spleen-derived activated T and B
lymphocytes. It has been shown that Fas selectively kills activated
IgG
+ B lymphocytes specific for parasite antigens [70]. Moreover,
CD4
+ and CD8
+ T lymphocytes are affected by Fas-induced
apoptosis, since activated T lymphocytes increase Fas, FasL
expression, and caspase-8 activation in acute infection [51,68].
Blockade of FasL interaction partially increases CD4
+ T
lymphocyte recovery, in vitro and in vivo [51]. Moreover, in vivo
administration of anti-FasL blocked AICD and enhanced T CD8
proliferation in infected mice [71]. Blockade of activated T CD8
death increased IFN-c secretion in initial stages and IL-4/IL-10
secretion in latter stages of infection [71]. Moreover, it has been
shown that IFN-c is able to promote splenocyte apoptosis by
increasing Fas/Fas-L expression, as well as by nitric oxide (NO)-
mediated cell death [72]. In fact, NO synthesis in acute T. cruzi
infection is able to modulate immune response, suppressing T cell
proliferation and inducing lymphocyte apoptosis [72–74]. In
Figure 3. Splenectomy increases host’s susceptibility to T. cruzi
infection. BALB/c mice were submitted to surgery to remove the
spleen (SX). Sham-operated mice were used as controls. Ten days after
surgery, mice were infected intraperitoneally with 2610
5 metacyclic
trypomastigote forms of Dm28c clone of T. cruzi. Parasitemia was
followed during acute phase. In the splenectomized animals, parasit-
emia was significantly higher, as compared to the sham-operated
infected counterparts. Kinetic points with significant differences
between SX (n=07, filled line) and sham-operated (n=05, dashed line)
groups are indicated. Data were compared by Student’s t test for
independent samples using a Sigma Plot for Windows (version 4.01)
package. For parasitemia, data were transformed to parasites/ml for
statistical analysis. Data were considered significant if p values were
,0.05 (*). Data represent mean6standard error. All experiments and
animal handling were conducted according to protocols approved by
the Oswaldo Cruz Foundation Committee on the Use of Animals.
doi:10.1371/journal.pntd.0000417.g003
Box 1. Methods
The papers cited in this manuscript were selected based
on the following criteria:
1. Stringency of the papers in relation to the subjects
discussed
2. High quality of the papers
3. Papers indexed in the PubMed database
www.plosntds.org 5 July 2009 | Volume 3 | Issue 7 | e417Figure 4. Regional dynamics of immune responses in lymphoid organs following acute experimental T. cruzi infection.
doi:10.1371/journal.pntd.0000417.g004
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PBMC death and low proliferative capacity of these cells to T. cruzi
antigens [75].
Lymphocyte apoptosis in T. cruzi infection favors the parasite
rather than the host, since phagocytic clearance of apoptotic cells
increases T. cruzi replication inside macrophages [52,76,77].
Several groups analyzed the pattern of immune response in the
spleen of T. cruzi-infected mice. On the other hand, there are few
reports on spleen involvement in patients with Chagas disease. In
humans, analyses of the spleen are based on chronic patient
autopsies. The few data in the literature in humans indicate that
spleens from chronic patients are increased in size and weight,
with increased areas of lymphoid follicles and thromboembolic
phenomena [78,79].
All together, these data indicate that splenocytes are involved in
the control of parasite load in infection. Moreover, processes of
polyclonal activation, AICD, and disturbances in cytokine
production are also observed in the spleen upon T. cruzi infection.
Concluding Remarks and Perspectives
T. cruzi infection represents a well-documented example of a
systemic infectious process. It is usually reported that immune
responses mounted in the spleen or in a particular group of lymph
nodes represent the immune response of the host. In this review,
we unravel the intrinsic importance of specific (and distinct)
microenvironments that exist in each lymphoid tissue and propose
that immune response in this infection is complex and variable.
After conducting a meta-analysis of studies (see Methods in Box 1)
performed in the thymus, MLN, SCLN, and spleen, it seems clear
that each lymphoid organ has local differences in ratios of
lymphocyte expansion that can be related to regional cytokine
production and cell death (see Figure 4). Although the reason(s)
accounting for these local variations remain unknown, microen-
vironmental factors are likely involved, including distinct lympho-
cyte distribution, antigen drainage, or specific types of antigen
presenting cells in each lymphoid organ. This actually represents
an open and interesting field for future studies.
The most affected cytokine in acute T. cruzi infection is IL-2, an
important growth factor for T lymphocytes that is suppressed in
the thymus, MLN, and spleen, but not in SCLN. The mechanism
involved in IL-2 deprivation in T. cruzi infection is still unknown.
One possible mechanism involved in IL-2 suppression is the
differential distribution of regulatory T cells (T reg cells) among
lymphoid organs in infection, since IL-2 could be produced in
normal levels and be sequestered by CD25
high CD4 T reg cells. In
a non-infective model, it was shown that T reg cells consume but
do not produce IL-2 [80–83]. In fact, previous studies in T. cruzi
infection demonstrated the presence of suppressive lymphocytes in
secondary lymphoid organs [66], and T reg cells were shown to be
present in the spleen of infected mice [84]. Moreover, it was
recently shown that T regs promote cytokine deprivation-induced
apoptosis in T cells [80]. This mechanism might be associated with
the thymus and MLN atrophies in infected mice.
It seems conceivable that the differences herein summarized in
the regional immune responses to the parasite may play a role in
the pathophysiology of Chagas disease, including in the evolution
of the tissue lesions. Quantitative differences in the expansion
versus apoptosis of regulatory T cells may be relevant candidates
in the differential control of tissue lesions in specific sites of the
organisms. Also, the cytokine microenvironment that dendritic
cells will interact with in a given secondary lymphoid organ will
possibly drive, at least partially, its fate in terms of the antigen
presenting function. These are open fields for further investigation
in both experimental models and in human Chagas disease.
In summary, identifying the factors that drive antigen-specific T
lymphocyte expansion and characterizing the mechanisms that
result in the cessation of expansion will be relevant to better
understanding of the molecular mechanisms underlying regional
lymphocyte dynamics secondary to T. cruzi infection, which will
hopefully contribute to the design of novel immune intervention
strategies to control pathology in this unique infection.
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